title: Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
abstract: We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10-15 d, with a mean reduction of >or=1.6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach.
authors.affiliation: Department of Internal Medicine, Division of Infectious Diseases, Haus 11, University of Cologne, Joseph-Stelzmann-Strasse 9, D-50924 Cologne, Germany.
authors.forename: Gerd
authors.initials: G
authors.lastname: Fätkenheuer
authors.forename: Anton L
authors.initials: AL
authors.lastname: Pozniak
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Johnson
authors.forename: Andreas
authors.initials: A
authors.lastname: Plettenberg
authors.forename: Schlomo
authors.initials: S
authors.lastname: Staszewski
authors.forename: Andy I M
authors.initials: AI
authors.lastname: Hoepelman
authors.forename: Michael S
authors.initials: MS
authors.lastname: Saag
authors.forename: Frank D
authors.initials: FD
authors.lastname: Goebel
authors.forename: Jürgen K
authors.initials: JK
authors.lastname: Rockstroh
authors.forename: Bruce J
authors.initials: BJ
authors.lastname: Dezube
authors.forename: Tim M
authors.initials: TM
authors.lastname: Jenkins
authors.forename: Christine
authors.initials: C
authors.lastname: Medhurst
authors.forename: John F
authors.initials: JF
authors.lastname: Sullivan
authors.forename: Caroline
authors.initials: C
authors.lastname: Ridgway
authors.forename: Samantha
authors.initials: S
authors.lastname: Abel
authors.forename: Ian T
authors.initials: IT
authors.lastname: James
authors.forename: Mike
authors.initials: M
authors.lastname: Youle
authors.forename: Elna
authors.initials: E
authors.lastname: van der Ryst
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D019540:Area Under Curve; D065100:CCR5 Receptor Antagonists; D017322:Clinical Trials, Phase II as Topic; D003510:Cyclohexanes / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D000077592:Maraviroc; D012367:RNA, Viral / Q000097:blood; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D019562:Viral Load / Q000706:statistics & numerical data
chemical_list: D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D012367:RNA, Viral; D014230:Triazoles; D000077592:Maraviroc